Tralokinumab for moderate-to-severe atopic dermatitis patients: first daily practice results.

Anne R SchlösserMadena ShareefJill OlydamTamar E C NijstenDirk Jan Hijnen

Published in: Clinical and experimental dermatology (2023)

Tralokinumab was found effective in most patients in this difficult-to-treat, severe AD daily practice cohort. Interestingly, tralokinumab was also found to be effective in 50% of patients that previously experienced insufficient response or adverse events with dupilumab.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
healthcare
atopic dermatitis
prognostic factors
early onset
patient reported outcomes
quality improvement